NEO6860 / AazeinTx - LARVOL DELTA

TRPV1 Receptor Modulators: Emerging Therapies for Neuropathic, Osteoarthritic, and Perioperative Pain. (PubMed, CNS Drugs) - "Promising pharmaceutical agonists for pain include low- and high-dose capsaicin formulations, resiniferatoxin, CNTX-4975, and vocacapsaicin. Potentially applicable antagonist drugs include NEO6860, Mavatrep, ACD-440, AJH-2947, DWP05195, and XEN-DO501. As our understanding of TRPV1 channels has continued to increase since the initial discovery, we are at last beginning to see some positive clinical developments for TRPV1 drugs in the realm of neuropathic, post-operative, musculoskeletal, and cancer pain."

Journal • Musculoskeletal Diseases • Musculoskeletal Pain • Oncology • Osteoarthritis • Pain

adMare and AazeinTx Inc. Sign Global Exclusive Agreement for Promising Acute Asthma Treatment (NEO6860) (Canada Newswire) - "adMare BioInnovations ('adMare') and AazeinTx Inc. ('AazeinTx') have closed a global exclusive licensing transaction for a promising acute asthma treatment. Under the agreement, AazeinTx has acquired all rights to NEO6860...Based on Wilson's preclinical research, AazeinTx proposes to bring a pill-based form of NEO6860 to humans as a rapid, effective, and disruptive technology to treat asthma."

Licensing / partnership • Asthma • Respiratory Diseases

Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysis. (PubMed, Pharmacol Ther) - "We also conducted a meta-analysis of T data from human trials and found that polymodal TRPV1 antagonists (ABT-102, AZD1386, and V116517) increase T, whereas the mode-selective blocker NEO6860 does not. Several strategies of harnessing the thermoregulatory effects of TRPV1 antagonists in humans are discussed."

Journal • Retrospective data • Review